Y-mAbs Therapeutics, Inc. (YMAB)
NASDAQ: YMAB · Real-Time Price · USD
4.070
+0.180 (4.63%)
At close: May 12, 2025, 4:00 PM
4.070
0.00 (0.00%)
After-hours: May 12, 2025, 4:00 PM EDT
Y-mAbs Therapeutics Revenue
In the year 2024, Y-mAbs Therapeutics had annual revenue of $87.69M with 3.38% growth. Y-mAbs Therapeutics had revenue of $26.50M in the quarter ending December 31, 2024, with 13.41% growth.
Revenue (ttm)
$87.69M
Revenue Growth
+3.38%
P/S Ratio
1.97
Revenue / Employee
$843,125
Employees
104
Market Cap
184.04M
Revenue Chart
Revenue History
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 410.06B |
Johnson & Johnson | 89.33B |
Merck & Co. | 63.92B |
AbbVie | 57.37B |
AstraZeneca | 54.98B |
Novartis AG | 53.22B |
Eli Lilly and Company | 49.00B |
Novo Nordisk | 43.92B |
YMAB News
- 5 days ago - Y-mAbs Announces Update to National Comprehensive Cancer Network® (NCCN®) Clinical Practice Guidelines in Oncology for Neuroblastoma to Include Naxitamab-gqgk (DANYELZA®) - GlobeNewsWire
- 6 days ago - Y-mAbs to Announce First Quarter 2025 Financial and Operating Results on May 13, 2025 - GlobeNewsWire
- 15 days ago - Y-mAbs Presents Translational Pharmacokinetics of CD38-SADA from Pretargeted RIT Platform at 2025 American Association for Cancer Research (AACR) Annual Meeting - GlobeNewsWire
- 17 days ago - Y-mAbs Announces First Patient Dosed in Phase 1 Clinical Trial Evaluating CD38-SADA Pre-targeted Radioimmunotherapy in Relapsed/Refractory Non-Hodgkin Lymphoma - GlobeNewsWire
- 4 weeks ago - Y-mAbs Therapeutics: A Yawn From The Market Means Opportunity - Seeking Alpha
- 2 months ago - Y-mAbs Therapeutics, Inc. (YMAB) Q4 2024 Earnings Call Transcript - Seeking Alpha
- 2 months ago - Y-mAbs Reports Fourth Quarter 2024 Financial Results and Recent Corporate Developments - GlobeNewsWire
- 2 months ago - Y-mAbs Announces Publication of Phase 2 Interim Results in Nature Communications - GlobeNewsWire